573 related articles for article (PubMed ID: 25574081)
1. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.
Li XL; Zhou J; Chen ZR; Chng WJ
World J Gastroenterol; 2015 Jan; 21(1):84-93. PubMed ID: 25574081
[TBL] [Abstract][Full Text] [Related]
2. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-552 links Wnt signaling to p53 tumor suppressor in colorectal cancer.
Kwak B; Kim DU; Kim TO; Kim HS; Kim SW
Int J Oncol; 2018 Oct; 53(4):1800-1808. PubMed ID: 30066856
[TBL] [Abstract][Full Text] [Related]
4. Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells.
Abu El Maaty MA; Strassburger W; Qaiser T; Dabiri Y; Wölfl S
Mol Carcinog; 2017 Nov; 56(11):2486-2498. PubMed ID: 28618116
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone I induces human colorectal cancer cell apoptosis: The potential roles of Aurora A-p53 and survivin-mediated signaling pathways.
Lu M; Wang C; Wang J
Int J Oncol; 2016 Aug; 49(2):603-10. PubMed ID: 27279458
[TBL] [Abstract][Full Text] [Related]
6. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.
Li XL; Zhou J; Chan ZL; Chooi JY; Chen ZR; Chng WJ
Oncotarget; 2015 Nov; 6(34):36689-99. PubMed ID: 26452133
[TBL] [Abstract][Full Text] [Related]
7. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H
Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor functions of miR-133a in colorectal cancer.
Dong Y; Zhao J; Wu CW; Zhang L; Liu X; Kang W; Leung WW; Zhang N; Chan FK; Sung JJ; Ng SS; Yu J
Mol Cancer Res; 2013 Sep; 11(9):1051-60. PubMed ID: 23723074
[TBL] [Abstract][Full Text] [Related]
9. microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway.
Ma Q; Wang X; Li Z; Li B; Ma F; Peng L; Zhang Y; Xu A; Jiang B
Oncol Rep; 2013 Apr; 29(4):1652-8. PubMed ID: 23380758
[TBL] [Abstract][Full Text] [Related]
10. ArhGAP30 promotes p53 acetylation and function in colorectal cancer.
Wang J; Qian J; Hu Y; Kong X; Chen H; Shi Q; Jiang L; Wu C; Zou W; Chen Y; Xu J; Fang JY
Nat Commun; 2014 Aug; 5():4735. PubMed ID: 25156493
[TBL] [Abstract][Full Text] [Related]
11. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC.
Voorneveld PW; Kodach LL; Jacobs RJ; van Noesel CJ; Peppelenbosch MP; Korkmaz KS; Molendijk I; Dekker E; Morreau H; van Pelt GW; Tollenaar RA; Mesker W; Hawinkels LJ; Paauwe M; Verspaget HW; Geraets DT; Hommes DW; Offerhaus GJ; van den Brink GR; Ten Dijke P; Hardwick JC
Br J Cancer; 2015 Jan; 112(1):122-30. PubMed ID: 25393365
[TBL] [Abstract][Full Text] [Related]
12. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Ohashi T; Idogawa M; Sasaki Y; Suzuki H; Tokino T
Mol Cancer Res; 2013 Dec; 11(12):1554-63. PubMed ID: 24140838
[TBL] [Abstract][Full Text] [Related]
13. A Novel Inhibitor Targets Both Wnt Signaling and ATM/p53 in Colorectal Cancer.
Cheng J; Dwyer M; Okolotowicz KJ; Mercola M; Cashman JR
Cancer Res; 2018 Sep; 78(17):5072-5083. PubMed ID: 30032112
[TBL] [Abstract][Full Text] [Related]
14. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
[TBL] [Abstract][Full Text] [Related]
15. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.
Li H; Zhang J; Tong JHM; Chan AWH; Yu J; Kang W; To KF
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795192
[TBL] [Abstract][Full Text] [Related]
18. Functional repair of p53 mutation in colorectal cancer cells using trans-splicing.
He X; Liao J; Liu F; Yan J; Yan J; Shang H; Dou Q; Chang Y; Lin J; Song Y
Oncotarget; 2015 Feb; 6(4):2034-45. PubMed ID: 25576916
[TBL] [Abstract][Full Text] [Related]
19. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
[TBL] [Abstract][Full Text] [Related]
20. PMN inhibits colorectal cancer cells through inducing mitotic arrest and p53-dependent apoptosis via the inhibition of tubulin polymerization.
Wu X; Shen Y
Biochem Biophys Res Commun; 2018 May; 499(4):927-933. PubMed ID: 29626471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
